Galibra Neuroscience has achieved a significant regulatory milestone after receiving both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for its investigational gene therapy targeting Succinic Semialdehyde Dehydrogenase (SSADH) deficiency, a rare inherited neurological disorder with no approved disease-modifying treatment.

SSADH deficiency is caused by mutations in the ALDH5A1 gene, disrupting normal Gamma-Aminobutyric Acid (GABA) metabolism and leading to the accumulation of toxic neuroactive metabolites. The disorder is associated with intellectual disability, autism spectrum disorder, epilepsy and a range of neurological and psychiatric complications. Current treatment options are limited to symptom management.

The FDA's Orphan Drug Designation is granted to therapies intended to treat rare diseases and offers incentives such as tax credits for qualified clinical testing, exemptions from certain regulatory fees, and up to seven years of market exclusivity upon approval. Meanwhile, the Rare Pediatric Disease Designation is awarded to therapies targeting serious or life-threatening rare diseases affecting children and may qualify the developer for a Priority Review Voucher if the therapy is approved and meets programme requirements.

Backed by promising preclinical research conducted at Boston Children's Hospital and Harvard Medical School, Galibra's programme is being developed as a potential first gene replacement therapy designed to address the underlying cause of SSADH deficiency rather than simply alleviating symptoms. The company is currently progressing IND-enabling studies while working closely with academic institutions and patient advocacy groups to initiate clinical trials.

Alexander Rotenberg, MD, PhD, Founder of Galibra Neuroscience, said, "Receiving both Orphan Drug and Rare Pediatric Disease Designations validates the importance of bringing innovative therapies to patients living with SSADH deficiency. These milestones reinforce our commitment to advancing a treatment that has the potential to address the underlying biology of this devastating disorder rather than simply managing its symptoms."

The programme has been developed in close collaboration with the SSADH Association and the broader international patient community, whose contributions have supported natural history research, patient engagement and therapeutic development.

"For families affected by SSADH deficiency, each milestone brings renewed hope," said Brad Hoffman, Founder and President of the SSADH Association. "These designations represent another step toward a future in which treatment can address the underlying disease rather than solely managing symptoms."

Galibra is also working with Aurelix Bio, which is providing strategic support in clinical development, regulatory planning, translational medicin, and operational execution to accelerate the programme toward first-in-human studies.

Commenting on the milestone, Brandon M. Henry, MD, Aurelix Bio, said the FDA recognitions underscore both the seriousness of SSADH deficiency and the importance of advancing innovative therapies capable of targeting the disease's underlying biology.

With dual FDA designations now in place, Galibra Neuroscience plans to continue advancing its SSADH gene therapy programme toward clinical development, bringing renewed hope to patients and families affected by the rare disorder.